• A photo or image of the condition, or
• A description of symptoms (location, appearance, duration, associated symptoms, etc.)?

Clinical Summary

Primary Diagnosis: Rheumatoid Arthritis (RA)

• PIP joint involvement — RA characteristically involves MCP and PIP joints (as opposed to osteoarthritis, which favors DIP joints)
• Duration >6 months — chronic inflammatory arthritis meeting the time criterion in ACR/EULAR 2010 classification criteria
• RF positive — Rheumatoid factor is one of the major serological markers for RA
• ANA negative — argues strongly against SLE (which would also show anti-dsDNA positivity)
• Anti-dsDNA negative — further excludes lupus arthritis (which is also non-erosive and involves PIP/MCP joints but requires dsDNA+/ANA+)
• Female, young adult — RA has a female predominance (~3:1), peak onset 30–50 years

• Small joint involvement (PIP = high-scoring joint distribution)
• Positive RF → 2 points (high positivity)
• Symptom duration ≥6 weeks → 1 point
• Elevated acute phase reactants (would complete the score)

The c-ANCA Positive — How to Interpret It

1. Coexisting / Overlap: RA + ANCA-associated Vasculitis (AAV)

• RA can be complicated by systemic vasculitis, particularly affecting vasa nervorum and small vessels
• c-ANCA positivity raises the possibility of Granulomatosis with Polyangiitis (GPA, formerly Wegener's) overlap
• This would warrant investigation for: pulmonary nodules/infiltrates, sinusitis, saddle nose deformity, renal involvement (hematuria/proteinuria), and skin vasculitis

2. False positive or non-specific c-ANCA

• Low-titer c-ANCA can occur in RA without true vasculitis (~5–10% of RA patients)
• If the patient has no systemic features of vasculitis, this may be a non-specific finding

Differential Diagnoses to Exclude

Recommended Workup

1. Anti-CCP (anti-citrullinated protein antibody) — most specific test for RA (~95% specificity); if positive, confirms RA with high confidence
2. CRP / ESR — assess inflammatory activity
3. Hand X-rays — look for periarticular osteopenia, joint space narrowing, erosions
4. Urinalysis + renal function — screen for renal vasculitis given c-ANCA positivity
5. Chest X-ray / CT chest — rule out pulmonary granulomas if GPA suspected
6. ENT evaluation — nasal/sinus involvement if GPA considered

Bottom Line

Management of Rheumatoid Arthritis

Step 1: Non-Pharmacological Measures

• Patient education and counseling on disease course
• Physiotherapy and occupational therapy — preserve joint function and range of motion
• Splinting of inflamed joints during acute flares
• Exercise to maintain muscle strength
• Smoking cessation (smoking worsens RA severity and reduces DMARD efficacy)
• Nutritional support; calcium + vitamin D supplementation (especially if on steroids)

Step 2: Pharmacological Management

A. Symptomatic Relief (while awaiting DMARD effect)

Steroids should not exceed 7.5 mg/day long-term. Even doses as low as 2.8 mg/day over 5 years are associated with serious infections. (— Katzung's Basic and Clinical Pharmacology, 16th Ed)

B. Disease-Modifying Antirheumatic Drugs (DMARDs) — Cornerstone of Treatment

Conventional Synthetic DMARDs (csDMARDs)

C. Biologic DMARDs (bDMARDs) — for Moderate-to-Severe or MTX-Refractory Disease

TNF-α Inhibitors (first-line biologics)

Non-TNF Biologics (for TNF failure or contraindication)

D. Targeted Synthetic DMARDs (tsDMARDs) — JAK Inhibitors

Step 3: Treatment Algorithm (ACR 2015 Guidelines)

Early RA (low disease activity)
    → MTX monotherapy

Early RA (moderate-to-severe)
    → MTX ± short-term glucocorticoids
    → If inadequate response in 3 months → add/switch DMARD

Established RA, MTX failure
    → Triple csDMARD therapy
       OR
    → MTX + TNF inhibitor
       OR
    → MTX + non-TNF biologic / JAK inhibitor

Refractory or severe RA
    → Rituximab + MTX
    → Consider cyclophosphamide (reserved for life-threatening cases)

Step 4: Monitoring

Special Considerations for This Patient

1. Start MTX early — the standard anchor drug. Add folic acid to reduce toxicity
2. Avoid leflunomide if pregnancy is a possibility (teratogenic)
3. c-ANCA monitoring — if systemic vasculitic features emerge, consider Rituximab (which also targets B-cells producing ANCA and RF — dual benefit)
4. Low-dose prednisone as a bridge while awaiting MTX effect (4–6 weeks)
5. If inadequate response at 3 months → escalate to triple therapy or TNF inhibitor + MTX